Matt Zuga is CFO at Acumen Pharmaceuticals, Inc. (ABOS). They have made 2 open-market trades across 2 companies since 2019, most recently 2026-01-22.
CIK 0001790214
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.1M since 2019, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABOS | 304,924 | $515K |
| TELA | 498,606 | $483K |
| Total | $998K |
Shares reported on the most recent Form 4, priced at the 2026-01-23 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABOS | SELL · 10b5-1 | 2026-01-21 | 2026-01-23 | $1.83 | $8K | +1.7% | +7.1% | +11.0% |
| ABOS | SELL · 10b5-1 | 2026-01-08 | 2026-01-12 | $1.82 | $13K | +15.1% | +48.8% | +46.2% |
| ABOS | SELL | 2026-01-05 | 2026-01-07 | $1.97 | $29K | -4.6% | +23.1% | +34.4% |
| ABOS | SELL · 10b5-1 | 2025-01-21 | 2025-01-23 | $1.70 | $57K | -14.5% | -19.7% | -41.0% |
| ABOS | SELL · 10b5-1 | 2025-01-03 | 2025-01-07 | $1.84 | $24K | -9.9% | -18.8% | -42.0% |
| ABOS | SELL · 10b5-1 | 2024-01-18 | 2024-01-19 | $3.71 | $16K | -11.9% | -8.0% | -12.5% |
| TELA | BUY | 2019-11-08 | 2019-11-13 | $13.00 | $1.1M | -6.0% | -7.0% | +24.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.